SEARCH

SEARCH BY CITATION

FilenameFormatSizeDescription
epi12391-sup-0001-TableS1-6.docxWord document24K

Table S1. Exclusion criteria.

Table S2. Baseline demographic and epilepsy characteristics and concomitant antiepileptic drugs (overall ITT population, ITT focal population, and ITT generalized population).

Table S3. Dose levels of patients during maintenance (ITT population).

Table S4. Psychiatric adverse events in ≥1% of patients in either treatment group during the 16-week treatment period (ITT population).

Table S5. Efficacy analyses over the 16-week treatment period stratified by concomitant levetiracetam use (ITT focal seizure population).

epi12391-sup-0002-Kwanetal.pptxapplication/pptx127K 

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.